Mixed connective tissue disease medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The treatment of patients with MCTD is organ [[Specificity (tests)|specific]] and depends on kind of internal organ involvement, phase of the disease, and rate of progression. Treatment strategies must follow conventional therapies that are used for similar problems in other [[Rheumatology|rheumatic]] diseases ([[systemic lupus erythematosus]], [[scleroderma]], [[polymyositis]]). Patients usually react to low doses of [[Steroid|steroids]] and [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]], in combination with [[Immunosuppressive drug|immunosuppressive drugs]] or [[Biology|biologic]] agents. In [[refractory]] cases or in severe clinical conditions, [[Antibody|immunoglobulins]], [[Chemotherapy|cytotoxic agents]] or [[Biology|biologic]] drugs can be administered | The treatment of patients with MCTD is organ [[Specificity (tests)|specific]] and depends on kind of internal organ involvement, phase of the disease, and rate of progression. Treatment strategies must follow conventional therapies that are used for similar problems in other [[Rheumatology|rheumatic]] diseases ([[systemic lupus erythematosus]], [[scleroderma]], [[polymyositis]]). Patients usually react to low doses of [[Steroid|steroids]] and [[Non-steroidal anti-inflammatory drug|non-steroidal anti-inflammatory drugs]], in combination with [[Immunosuppressive drug|immunosuppressive drugs]] or [[Biology|biologic]] agents. In [[refractory]] cases or in severe clinical conditions, [[Antibody|immunoglobulins]], [[Chemotherapy|cytotoxic agents]] or [[Biology|biologic]] drugs can be administered. | ||
==Medical Therapy== | ==Medical Therapy== | ||
* The treatment of patients with MCTD is organ [[Specificity (tests)|specific]] and depends on:<ref name="pmid24353496">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | * The treatment of patients with MCTD is organ [[Specificity (tests)|specific]] and depends on:<ref name="pmid24353496">{{cite journal |vauthors=Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E |title=Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl |journal=Postepy Dermatol Alergol |volume=30 |issue=5 |pages=329–36 |date=October 2013 |pmid=24353496 |pmc=3858664 |doi=10.5114/pdia.2013.38365 |url=}}</ref> | ||
** | ** Internal organ involvement | ||
** Phase of the disease | ** Phase of the disease | ||
** Rate of progression | ** Rate of progression | ||
Revision as of 20:30, 30 April 2018
|
Mixed connective tissue disease Microchapters |
|
Differentiating Mixed connective tissue disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Mixed connective tissue disease medical therapy On the Web |
|
American Roentgen Ray Society Images of Mixed connective tissue disease medical therapy |
|
Directions to Hospitals Treating Mixed connective tissue disease |
|
Risk calculators and risk factors for Mixed connective tissue disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
The treatment of patients with MCTD is organ specific and depends on kind of internal organ involvement, phase of the disease, and rate of progression. Treatment strategies must follow conventional therapies that are used for similar problems in other rheumatic diseases (systemic lupus erythematosus, scleroderma, polymyositis). Patients usually react to low doses of steroids and non-steroidal anti-inflammatory drugs, in combination with immunosuppressive drugs or biologic agents. In refractory cases or in severe clinical conditions, immunoglobulins, cytotoxic agents or biologic drugs can be administered.
Medical Therapy
- The treatment of patients with MCTD is organ specific and depends on:[1]
- Internal organ involvement
- Phase of the disease
- Rate of progression
- Treatment strategies must follow conventional therapies that are used for similar problems in other rheumatic diseases (systemic lupus erythematosus, scleroderma, polymyositis).[2]
- For more information about treatment of systemic lupus erythematosus click here.
- For more information about treatment of scleroderma click here.
- For more information about treatment of polymyositis click here.
- Patients usually react to low doses of steroids and non-steroidal anti-inflammatory drugs, in combination with immunosuppressive drugs or biologic agents (monoclonal antibodies).[1]
- In refractory cases or in severe clinical conditions, immunoglobulins, cytotoxic agents (such as cyclophosphamide) or biologic drugs can be administered.[3]
- Plasmapheresis may be a therapeutic option, especially when it is combined with agents that can block production of pathogenic autoantibodies, such as rituximab (a monoclonal antibody anti-CD20 which can modulate the disease activity).
References
- ↑ 1.0 1.1 Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.
- ↑ Kim P, Grossman JM (August 2005). "Treatment of mixed connective tissue disease". Rheum. Dis. Clin. North Am. 31 (3): 549–65, viii. doi:10.1016/j.rdc.2005.04.008. PMID 16084325.
- ↑ Latuśkiewicz-Potemska J, Zygmunt A, Biernacka-Zielińska M, Stańczyk J, Smolewska E (October 2013). "Mixed connective tissue disease presenting with progressive scleroderma symptoms in a 10-year-old girl". Postepy Dermatol Alergol. 30 (5): 329–36. doi:10.5114/pdia.2013.38365. PMC 3858664. PMID 24353496.